Table 3.

Frequencies of mutations in total patient population and distribution of mutations across patient groups A–D. We classified patients initially on the basis of KRAS status, followed by NRAS, BRAF, and finally PIK3CA. According to these criteria, KRAS mutations may also have NRAS, BRAF, and PIK3CA mutations (KRAS MT +/–NRAS MT +/–BRAF MT +/–PIK3CA MT). NRAS mutations are KRAS wildtype but may have mutations in BRAF and PIK3CA (KRAS WT + NRAS MT +/–BRAF MT +/–PIK3CA MT). BRAF mutants are KRAS and NRAS wildtype but may have mutations in PIK3CA (KRAS WT + NRAS WT + BRAF MT +/–PIK3CA MT). PIK3CA mutants are wildtype for KRAS, NRAS, and BRAF. Quadruple wildtype patients are KRAS, NRAS, BRAF, and PIK3CA wildtype. TP53 mutation status is independent of other mutations

	% of total patient population	% of total in patient group A	% of total in patient group B	% of total in patient group C	% of total in patient group D
TP53 MT	51.8%	6.9%	32.7%	19.8%	40.6%
BRAF MT	9.2%	72.2%	11.1%	5.5%	11.1%
KRAS MT	41.0%	7.5%	30%	10%	52.5%
NRAS MT	6.7%	0%	15.4%	7.7%	76.9%
KRAS/NRAS MT	47.7%	6.5%	28.0%	9.7%	55.9%
PIK3CA MT	4.1%	50%	37.5%	0%	12.5%
Quadruple wildtype	39.0%	6.6%	26.3%	28.9%	38.2%